Immunotherapy in Patients With Early dMMR Rectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
- Status
- WITHDRAWN
- Phase
- PHASE1
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
- Status
- RECRUITING
- Phase
- PHASE2
EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
- Status
- COMPLETED
- Phase
- N/A
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
- Status
- RECRUITING
- Phase
- PHASE1
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Status
- RECRUITING
- Phase
- PHASE3
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
- Status
- RECRUITING
- Phase
- PHASE2
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
- Status
- RECRUITING
- Phase
- NA